Download Supplementary Information 1 (ppt 48K)

Martinez-Leal et al, Supplementary Material 1
Type of tumor (# cases)
15q21
Hepatocellular carcinoma (48) 45,83
Bladder carcinoma (51)
39,22
HNSCC (22)
62
Cervical carcinomas (67)
27
Ovarian tumor (LMP) (50)
Ovarian tumor (OC) (23)
Endometrial AC (37)
Oropharyngeal EC (25)
Renal CC (45)
Renal CC (19 primary tumors)
Renal CC (6 metastases)
Gliomas (142)
Glioblastoma multiforme (21)
Neuroblastoma (170)
Nasopharyngeal C (60)
7q35
14q32
8
19,4
8,3
24
50
18
11,5
22,2
18,7
38
58
66
20
>40
18
>30
p53 (17p13) PTEN (10q23) pRB (13q14) BRCA2 (13q12)
91,67
60,42
79,17
70,83
You et al, 2004
Natrajan et al, 2003
88
Beder et al, 2003
11
Kersemekers et al, 1998
2,8
5,2
Nakayama et al, 2001
15,3
12,5
Nakayama et al, 2001
26,09
18,18
5,56
Sirchia et al, 2000
47
13,3
46,7
Grati et al, 2000
Alimov et al, 2004
Alimov et al, 2004
Alimov et al, 2004
Dichamp et al, 2004
>50
>50
>50
>50
Hu et al, 2003
Van Limpt et al, 2003
>30
43
Shao et al, 2002
The genes identified in our loss of function screening are in chromosome locations involved in significative (>20%) allelic loss in different
tumors, according to data obtained in a CGH tumor database (see table 1, in supplementary information 2). Csn2 is located at 15q21.2 locus.
Loss of this region is frequently observed in a variety of tumors of different origins, having a higher incidence in lung, breast, brain and
colorectal carcinomas. The average incidence of loss (26.99%) is in the range observed for well known tumor suppressors such as pRB
(38.64%), PTEN (30.68%) or BRCA2 (24.01%). This observation is in agreement with the existence of a candidate tumor suppressor gene in the
15q21.2 locus. This hypothesis is further supported with more detailed cytogenetic studies using microsatellite probes to detect specific LOH.
Frequency of loss ranges from 27% in cervical carcinomas to 62% in head and neck squamous cell carcinomas (HNSCC) .
Aldose reductase gene is located at 7q35. This region has a lower incidence of loss in tumors, still being significant in some tumors such as
HNSCC (22.22%) (see supplementary information 3). LOH analysis show higher impact, specially in oropharingeal epithelial carcinoma, with a
50% of allelic loss (see table 2, in supplementary information). A similar situation accounts for BRF1, at 14q32.33. CGH analysis shows a
moderate loss, with a higher incidence (20.69%) in colorectal carcinomas. LOH data confirms this observation, giving higher values of allelic
loss (up to 66% in metastatic renal carcinoma) and affecting a variety of tumor types.